

## Chromosome Microarray (MaCGH) Laboratory Testing

Date: June 14, 2019

---

Effective Date: June 20, 2019

As UR Medicine Laboratory begins the transition to 211 Bailey Rd, the Microarray Laboratory will be immediately impacted. Due to the nature of the testing and the desire to maintain appropriate turn-around times, testing will be sent out to appropriate Reference Laboratories as of June 20, 2019. This change is temporary and we expect to be fully operational and bring testing back in-house August 1, 2019.

This temporary measure will otherwise NOT affect the process by which these tests are ordered, and there is no change to sample requirements.

Tests impacted include: MACGH + SNP (180K + SNP), Array CGH (aCGH), Microarray CGH

For questions or concerns please contact: M.Anwar Iqbal, Ph.D (Director) 585-758-0422 or Mary Shaver (Supervisor) 585-758-0492.

From: M. Anwar Iqbal, Ph.D., FFACMG  
Director, MicroArray, UR Medicine Labs  
University of Rochester Medical Center  
Phone: (585) 729-2440  
Email: Anwar\_Iqbal@urmc.rochester.edu



Diagnosis:	Current Tests:	Reference Lab:	New Test Name:	Description:	Includes:	Specimen Requirements
CLL	NGS panel (previously: TP53, NOTCH1, SF3B1)	Cancer Genetics Incorporated (CGI)	FCLL	NGS panel to evaluate Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma biomarkers for impact on prognosis	TP53, NOTCH1, SF3B1, BIRC3, ATM, MYD88, Card11 genes	1 lav EDTA blood or bone marrow also acceptable FFPE block or 5-10 FFPE section curls
CLL	IGHVM	Cancer Genetics Incorporated (CGI)	IGHVG	Detection of hyper-mutation in the IGHV gene to serve as a prognostic indicator	IGHV Mutation Analysis	1 lav EDTA blood or bone marrow
Lung Tumor	EGFR, KRAS, BRAF, Reflex NRAS	Mayo Clinic Laboratories	LUNGFP	NGS panel to evaluate samples for somatic mutations that may respond to targeted therapies	EGFR, BRAF, KRAS, HRAS, NRAS, ALK, ERBB2, and MET	Tissue block(preferred) or cytology slide
Myeloid Malignancies	NGS Myeloid panel, CEBPA, FLT3, IDH1, IDH2, NPM1	Mayo Clinic Laboratories	NGSHM	NGS panel to evaluate hematologic neoplasms, specifically of myeloid origin (eg, acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, myelodysplastic/myeloproliferative neoplasm)	ANKRD26, ASXL1, BCOR, CALR, CBL, CEBPA, CSF3R, DDX41, DNMT3A, ELANE, ETNK1, ETV6, EZH2, FLT3, GATA1, GATA2, IDH1, IDH2, JAK2, KDM6A, KIT, KRAS, MPL, NPM1, NRAS, PHF6, PTPN11, RAD21, RUNX1, SETBP1, SH2B3, SF3B1, SRP72, SMC3, SRSF2, STAG2, TERT, TET2, TP53, U2AF1, WT1, and ZRSR2.	1 lav EDTA blood or bone marrow
Low-grade B-cell lymphoma	MYD88	Mayo Clinic Laboratories	LPLFX	Establishing the diagnosis of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM)	MYD88 there is a Reflex test offered CXCR4 (CXCFX)	1 lav EDTA blood or bone marrow or paraffin-embedded tissue/bone marrow
Colorectal Cancer	KRAS, BRAF	Mayo Clinic Laboratories	RASFP	Evaluation of mutations that may respond to gene targeted therapy	BRAF (exons 11 and 15), HRAS (exons 2 and 3), NRAS (exons 2, 3, 4), and KRAS (exons 2, 3, 4) genes. This includes, but is not limited to, the testing of somatic mutations in KRAS codons 12, 13, 59, 61, 117, 146; NRAS codons 12, 13, 59, 61, 146; HRAS codons 12, 13, 61; and BRAF codons 594, 596, 600.	Tissue block(preferred) or cytology slide
Melanoma	BRAF	Mayo Clinic Laboratories	BRAFC	Identification of melanoma tumors that may respond to BRAF-targeted therapies (V600 mutations)	BRAF	Tissue block or tissue slides